Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

South Korean and Chinese investors join round into Oxford University spinout developing cancer vaccines.

Oxford Vacmedix UK Limited (OVM), a UK-based biopharma company focused on the development of cancer vaccines, has completed its Series A financing round of $12.5m (£9m) with a consortium of South Korean and Chinese investors.

OVM will use the funds to complete preclinical development and to enter Phase 1 clinical trials with its two lead vaccines, OVM-100 and OVM-200, focusing on unmet clinical need. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours. Both vaccines will be developed as single agents and in combination with immune-oncology agents. The company will also continue to develop its diagnostic kits for cellular immunity.

Find out more (Oxford University Innovation website)

Similar stories

AIMday in Women's Health - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Oxford BioEscalator celebrates three years of innovation

The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.

Immunology and AI drug discovery partnership agreed with Sensyne Health

The University has signed an agreement with Sensyne Health to conduct a multi-omics drug discovery research project in asthma. The project will be led by Dr Timothy Hinks and his team at the Nuffield Department of Medicine’s Respiratory Medicine Unit.

Oxford overseas research facility expands to include diagnostics and genetics testing centre

The Oxford-Suzhou Centre for Advanced Research, known as OSCAR, has marked another significant milestone with the launch of OSCAR-Prenetics Innovation and Technology Centre for Advanced Molecular Diagnostics (the OSCAR-Prenetics ITC).